다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

홈
인베스팅
주식
미국
NASDAQ
Dianthus Therapeutics Inc (DNTH)
Dianthus Therapeutics Inc (DNTH) 옵션

Dianthus Therapeutics Inc (DNTH)

97.60

-2.43

(-2.43%)

마감 11 7월 5:00AM

97.60

0.06

(0.06%)

시간외 거래: 8:59AM

Dianthus Therapeutics Inc ([symbol]) 옵션 체인

DNTH 실시간 옵션 플로우

콜

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
50.00	45.00	49.50	0.00	47.25	0.00	0.00 %	0	0	-
55.00	40.40	44.50	33.33	42.45	0.00	0.00 %	0	1	-
60.00	35.00	39.50	33.70	37.25	0.00	0.00 %	0	1	-
65.00	30.40	34.50	28.70	32.45	0.00	0.00 %	0	1	-
70.00	25.00	29.50	12.00	27.25	0.00	0.00 %	0	30	-
75.00	20.00	24.50	10.55	22.25	0.00	0.00 %	0	2	-
80.00	15.00	19.50	5.20	17.25	0.00	0.00 %	0	20	-
85.00	10.50	14.50	6.00	12.50	0.00	0.00 %	0	76	-
90.00	5.90	10.00	6.00	7.95	0.00	0.00 %	0	14	-
95.00	2.05	6.90	2.50	4.475	0.00	0.00 %	0	2	-
100.00	0.10	4.90	3.40	2.50	0.00	0.00 %	0	3	-
105.00	0.10	4.90	2.25	2.50	0.00	0.00 %	0	1	-
110.00	0.15	4.90	0.00	2.525	0.00	0.00 %	0	0	-
115.00	0.05	4.90	2.70	2.475	0.00	0.00 %	0	1	-
120.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
125.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
130.00	0.00	5.00	0.00	0.00	0.00	0.00 %	0	0	-
135.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
140.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
145.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-

개인 투자자를 위한 전문가급 도구.

프리미엄

풋

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
50.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
55.00	0.00	4.90	0.00	0.00	0.00	0.00 %	0	0	-
60.00	0.00	4.90	0.80	0.80	0.00	0.00 %	0	0	-
65.00	0.00	4.90	2.45	2.45	0.00	0.00 %	0	11	-
70.00	0.00	4.90	2.62	2.62	0.00	0.00 %	0	10	-
75.00	0.00	4.90	2.60	2.60	0.00	0.00 %	0	8	-
80.00	0.00	4.90	5.90	5.90	0.00	0.00 %	0	1	-
85.00	0.00	4.90	6.81	6.81	0.00	0.00 %	0	2	-
90.00	0.20	3.40	0.35	1.80	0.00	0.00 %	0	1	-
95.00	0.10	3.00	0.00	1.55	0.00	0.00 %	0	0	-
100.00	2.00	6.50	0.00	4.25	0.00	0.00 %	0	0	-
105.00	5.50	10.30	0.00	7.90	0.00	0.00 %	0	0	-
110.00	10.10	14.90	0.00	12.50	0.00	0.00 %	0	0	-
115.00	15.50	19.50	0.00	17.50	0.00	0.00 %	0	0	-
120.00	20.50	24.50	0.00	22.50	0.00	0.00 %	0	0	-
125.00	25.50	30.00	0.00	27.75	0.00	0.00 %	0	0	-
130.00	30.50	35.00	0.00	32.75	0.00	0.00 %	0	0	-
135.00	35.50	39.90	0.00	37.70	0.00	0.00 %	0	0	-
140.00	40.50	44.90	0.00	42.70	0.00	0.00 %	0	0	-
145.00	45.50	49.90	0.00	47.70	0.00	0.00 %	0	0	-

가장 활성
% 상승자
% 패자

기호	가격	볼륨
GMMGloba Mofy AI Ltd	US$ 4.57 (147.03%)	138.58M
JZXNJiuzi Holdings Inc	US$ 2.165 (85.04%)	146.27M
NVVENuvve Holding Corporation	US$ 13.50 (53.76%)	18.16M
AARDAardvark Therapeutics Inc	US$ 7.66 (53.20%)	4.09M
SUNESUNation Energy Inc	US$ 3.8201 (49.22%)	75.99M
HAOHaoxi Health Technology Ltd	US$ 0.3525 (-67.06%)	93.04M
JEM707 Cayman Holdings Ltd	US$ 0.54 (-51.79%)	7.76M
ELPWElong Power Holding Ltd	US$ 0.3003 (-46.94%)	92.78M
VRAXVirax Biolabs Group Ltd	US$ 4.08 (-35.85%)	1.75M
AFJKUAimei Health Technology Company Ltd	US$ 18.00 (-35.74%)	2
ZBAOZhibao Technology Inc	US$ 0.422 (42.57%)	325.25M
DFNST3 Defense Inc	US$ 0.117427 (-20.12%)	288.79M
NVDANVIDIA Corporation	US$ 210.96 (4.03%)	149.34M
JZXNJiuzi Holdings Inc	US$ 2.165 (85.04%)	146.27M
GMMGloba Mofy AI Ltd	US$ 4.57 (147.03%)	138.58M

iHub News

iHub News 4 월 전

Dianthus Therapeutics shares jump 25% after encouraging clinical trial updateMarch 9, 2026 10:15 AM
IH Market News
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported a fourth-quarter loss of $1.43 per share on Monday, while revenue totaled $280 thousand for the quarter ended December 31, 2025.Shares of the biotechnology company surged 25.05% in pre-market trading following the announcement.The company revealed it had reached an early GO decision in its Phase 3 CAPTIVATE trial evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The milestone was achieved after the study recorded 20 confirmed responders, with fewer than 40 of the planned participants completing the open-label Part A stage.The early GO determination came ahead of the previously expected second-quarter 2026 timeline and was based on trial criteria requiring a response rate of at least 50%. Dianthus said it expects to release guidance for the CAPTIVATE Part B top-line results by the end of 2026.“It is truly exciting to be part of a company developing potential best-in-disease therapies for patients suffering from severe autoimmune diseases,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics.For the full year 2025, Dianthus reported a net loss of $162.3 million, or $4.20 per share, compared with a net loss of $85.0 million, or $2.55 per share, in 2024.Research and development expenses rose to $145.6 million from $83.1 million year over year, primarily due to higher clinical trial costs and upfront milestone payments related to DNTH212.As of December 31, 2025, the company held $514.4 million in cash, cash equivalents and investments, which it expects will fund operations through 2028.Dianthus also plans to launch a Phase 3 registrational study of claseprubart in generalized Myasthenia Gravis in mid-2026, with top-line results anticipated in the second half of 2028.Dianthus Therapeutics stock price

Original: Dianthus Therapeutics shares jump 25% after encouraging clinical trial update

Monksdream

Monksdream 2 년 전

DNTH moving sideways

Monksdream

Monksdream 2 년 전

Dianthus Therapeutics

Abacus Mining and Explor... (PK)

5.500% Nts 30/04/54 144a

Morgan Stanley Finance L...

International bonds 5.95...

Westin Acquisition

United Internet (PK)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

ADVFN

계정이 있으신가요? 로그인

계정이 없으신가요? 등록

등록함으로써 나는 ADVFN의 이용 약관 을 읽고 이해했으며 이에 동의하며 개인 투자자임을 확인합니다.